X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder -BOSTON, (GLOBE NEWSWIRE) -- X4 Pharmaceuticals ...

X4 Pharmaceuticals, Inc.: X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of ...
News-Medical.Net on MSN

Textile-based system advances real-world cardiovascular monitoring

Cardiovascular diseases remain the leading global cause of mortality, claiming nearly 18 million lives each year. Early detection and continuous monitoring of blood pressure, vascular resistance, and ...